MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method

This publication has 35 references indexed in Scilit:

• Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
  New England Journal of Medicine, 2013
• Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience
  Haematologica, 2012
• The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange
  Transfusion, 2010
• Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience
  PLOS ONE, 2010
• AptaCDSS-E: A classifier ensemble-based clinical decision support system for cardiovascular disease level prediction
  Expert Systems with Applications, 2008
• Molecular Biology of ADAMTS13 and Diagnostic Utility of ADAMTS13 Proteolytic Activity and Inhibitor Assays
  Seminars in Thrombosis and Hemostasis, 2005
• Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura
  Blood, 2004
• An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations
  Thrombosis and Haemostasis, 2004
• Von Willebrand factor–cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura
  Blood, 2002
• Gene expression profiling predicts clinical outcome of breast cancer
  Nature, 2002